Softwr

Healthcare · head to head

PathAI vs UpToDate

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
UpToDate logo

UpToDate

Healthcare

Evidence-based clinical decision support for healthcare providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; UpToDate upToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.
  • They diverge on capability: PathAI covers AISight image management, UpToDate covers Clinical Evidence.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and UpToDate actually diverge.

Attributes where PathAI and UpToDate differ
AttributePathAIUpToDate
Pricing modelquotesubscription
PlatformsWebWeb, Mobile
FoundedUnknown1992

Identical on both: starting price (On request), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in UpToDate

  • Clinical Evidence
  • Drug Information
  • Calculators
  • Medical Images
  • Videos
  • CME Credits
  • EHR Systems
  • Mobile

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot UpToDate
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot UpToDate
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot UpToDate
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot UpToDate

UpToDate

  • Patient Carenot PathAI
  • Medical Recordsnot PathAI
  • Practice Managementnot PathAI
  • Telehealthnot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

UpToDate

  • UpToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

UpToDate

On request

No published plan breakdown. See the UpToDate review.

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose UpToDate if

  • You need clinical evidence.
  • You work on Web, Mobile.
  • You also want drug information.
UpToDate review

Questions people ask

Is PathAI or UpToDate better?
Neither clearly leads. PathAI starts at On request and UpToDate at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or UpToDate?
PathAI starts at On request and UpToDate at On request.
Does PathAI or UpToDate run on more platforms?
PathAI runs on Web. UpToDate runs on Web, Mobile.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what UpToDate is typically brought in for.
What can PathAI do that UpToDate cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management. UpToDate covers Clinical Evidence, Drug Information, Calculators, Medical Images.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on PathAI

More on UpToDate

Keep looking

Other head to heads